Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Cardea, HTG Molecular, Novigenix, Stilla Technologies

NEW YORK – Cardea announced this week that it has finalized its acquisition of Nanosens Innovations. The merger was first announced in September, along with the news that the companies planned to make their CRISPR-Chip-based Genome Sensor available through an early access program. Nanosens will continue to operate as a brand under the Cardea umbrella for the Genome Sensor and other tools the company plans to develop for the research market.

Immunotranscriptomics company Novigenix said this week that Helsana, the leading health insurance provider in Switzerland, has started coverage for Colox, the company's liquid biopsy test for the early detection of colorectal cancer. Individuals with the private outpatient supplementary insurance PRIMEO will be reimbursed for Colox. Colox is currently available in Switzerland through commercial partnerships with medical laboratories Unilabs and Dr Risch.

HTG Molecular Diagnostics announced this week that it will continue to abide by its existing obligations and complete all contracted work as part of a 2016 master assay development, commercialization, and manufacturing agreement with Qiagen subsidiary Qiagen Manchester. Tuscon, Arizona-based HTG said it will contract opportunities to develop new RNA companion diagnostics based on its EdgeSeq technology directly with BioPharma customers. The firm expects the opportunities to leverage the existing 2014 diagnostic development agreement with Illumina. If HTG's RNA companion diagnostic program leads to global commercialization, the firm will be able to freely partner with a number of third parties with respect to distribution and other commercialization activities.

Stilla Technologies said this week that it has established a new US subsidiary in Beverly, Massachusetts to enable direct commercial operations and distribution in the Americas, primarily for its Naica Crystal Digital PCR system. The new location will provide direct sales and support for American customers, including a demo lab and training center, and is being overseen by Ruth Szebries, the newly appointed general manager and vice president of commercial operations of the Americas.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.